Rapid Micro Biosystems Posts 11% Revenue Growth in Q2 2026 — Rapid Micro Biosystems, Inc.

Event summary

Q2 2026 revenue reached $8.1M, up 11% YoY from Q2 2025.
Placed four Growth Direct systems and completed nine validations in Q2 2026.
Consumable revenue increased over 20% year-over-year.
Achieved a record gross margin of 15%, up 11 percentage points YoY.
Reaffirmed full-year 2026 revenue guidance of $37M–$41M.

The big picture

Rapid Micro Biosystems' Q2 results reflect continued progress in its strategic priorities, particularly in margin expansion and recurring revenue growth. The company's focus on automation aligns with broader industry trends toward faster, safer healthcare product release, supported by favorable tailwinds such as U.S. reshoring and biomanufacturing capacity expansion.

What we're watching

Execution Risk: Whether the company can sustain its momentum in Growth Direct placements and validations through H2 2026.
Margin Expansion: The pace at which Rapid Micro Biosystems can achieve its full-year gross margin guidance of ~20%.
Industry Tailwinds: How U.S. reshoring and biomanufacturing capacity expansion will impact demand for automation solutions.